Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
Ney Carter Borges/LinkedIn
Feb 23, 2026, 15:59

Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“Antithrombotic Therapy in 2025: A Precision-Based Pharmacologic Update

The 2025 cardiovascular literature substantially refined antithrombotic strategies across acute coronary syndromes (ACS), atrial fibrillation (AF), and prosthetic valve management, emphasizing individualized risk stratification and bleeding mitigation .

In ACS, the Target-first trial demonstrated that discontinuing aspirin after one month of dual antiplatelet therapy (DAPT) and continuing potent P2Y12 inhibitor monotherapy reduced actionable bleeding (2.6% vs 5.6%, P equals .002) without increasing major adverse events (2.1% vs 2.2%).

Conversely, Neo-mindset showed that very early aspirin withdrawal within 4 days post-PCI, although reducing bleeding (2.0% vs 4.9%), failed to maintain non-inferiority for ischemic protection (MAE 7.0% vs 5.5%). These findings confirm that at least one month of DAPT remains essential after ACS.

In post-CABG patients (TACSI), ticagrelor plus aspirin did not reduce ischemic events compared with aspirin alone but doubled major bleeding (4.9% vs 2.2%).

The Celebrate trial further supported early pharmacologic platelet inhibition: pre-hospital subcutaneous zalunfiban improved coronary flow (P equals .012) and 30-day hierarchical outcomes (P equals .028) with only mild-to-moderate bleeding excess.

In AF, the Aquatic trial demonstrated that adding aspirin to oral anticoagulation (OAC) in stable chronic coronary syndrome increased major adverse events (16.9% vs 12.1%), major bleeding (10.2% vs 3.4%), and mortality.

Similarly, Adapt AF-DES confirmed the superiority of OAC monotherapy beyond 12 months after stenting.

In elderly frail patients, Combine-AF showed that switching from warfarin to a direct oral anticoagulant (DOAC) reduced intracranial hemorrhage (0.38%/year vs 1.33%/year) and fatal bleeding, at the cost of increased gastrointestinal bleeding.

Prestige-AF highlighted the complexity of anticoagulation after intracerebral hemorrhage: DOAC therapy markedly reduced ischemic stroke (0.83%/year vs 8.60%/year) but increased recurrent ICH (5.0%/year vs 0.82%/year), underscoring the need for individualized decisions.

In valvular disease, ENBALV demonstrated comparable short-term outcomes between edoxaban and warfarin after bioprosthetic valve surgery, while a randomized pilot study in mechanical valve thrombosis showed lower in-hospital and 1-year mortality with prolonged low-dose fibrinolysis compared with urgent surgery.

Collectively, 2025 data reinforce precision antithrombotic therapy—balancing ischemic benefit against bleeding risk through patient-specific, context-driven pharmacologic selection.”

Ney Carter Borges: Antithrombotic Therapy in 2025 - A Precision-Based Pharmacologic Update

Stay updated with Hemostasis Today.

ACS AF antithrombotic therapy bleeding disorders Cardiovascular Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Ney Carter Borges Valvular Disease
NewsFeed